BiotechTube

AXS-05 (dextromethorphan-bupropion) + Placebo

Phase 3Completed
0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Agitation in Patients With Dementia of the Alzheimer's Type

Conditions

Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation, Psychomotor

Trial Timeline

Jun 17, 2021 → Dec 21, 2024

NCT ID
NCT04947553

About AXS-05 (dextromethorphan-bupropion) + Placebo

AXS-05 (dextromethorphan-bupropion) + Placebo is a phase 3 stage product being developed by Axsome Therapeutics for Agitation in Patients With Dementia of the Alzheimer's Type. The current trial status is completed. This product is registered under clinical trial identifier NCT04947553. Target conditions include Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation, Psychomotor.

What happened to similar drugs?

2 of 13 similar drugs in Agitation in Patients With Dementia of the Alzheimer's Type were approved

Approved (2) Terminated (2) Active (9)
✅Quetiapine + Haloperidol + Lorazepam + CogentinAstraZenecaApproved
🔄Brexpiprazole, OPC-34712LundbeckPhase 3
🔄Brexpiprazole, OPC-34712 + Placebo Oral TabletLundbeckPhase 3
🔄BrexpiprazoleLundbeckPhase 3
❌AXS-05 (dextromethorphan-bupropion)Axsome TherapeuticsPhase 3
🔄AXS-05 + PlaceboAxsome TherapeuticsPhase 3
🔄AXS-05 + PlaceboAxsome TherapeuticsPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04947553Phase 3Completed

Competing Products

20 competing products in Agitation in Patients With Dementia of the Alzheimer's Type

See all competitors
ProductCompanyStageHype Score
ONO-2020 + PlaceboOno PharmaceuticalPhase 2
42
Quetiapine + Haloperidol + Lorazepam + CogentinAstraZenecaApproved
43
Brexpiprazole, OPC-34712LundbeckPhase 3
37
Brexpiprazole, OPC-34712 + Placebo Oral TabletLundbeckPhase 3
37
BrexpiprazoleLundbeckPhase 3
37
AXS-05 + Bupropion + PlaceboAxsome TherapeuticsPhase 2/3
35
AXS-05 (dextromethorphan-bupropion)Axsome TherapeuticsPhase 3
29
AXS-05 + PlaceboAxsome TherapeuticsPhase 3
37
AXS-05 + PlaceboAxsome TherapeuticsPhase 3
37
Pimavanserin 34 mg + Pimavanserin 20 mgAcadia PharmaceuticalsPhase 2
24
PimavanserinAcadia PharmaceuticalsPhase 2
32
Sublingual film containing Dexmedetomidine (BXCL501) + Placebo FilmBioXcel TherapeuticsPhase 3
30
BXCL501 + Matching PlaceboBioXcel TherapeuticsPhase 3
22
Sublingual film containing BXCL501 (Dexmedetomidine) + Placebo filmBioXcel TherapeuticsPhase 1
19
BXCL501 + Matching PlaceboBioXcel TherapeuticsPhase 3
30
BXCL501 + Matching PlaceboBioXcel TherapeuticsPhase 3
30
Sublingual film containing dexmedetomidine (BXCL501) + Placebo FilmBioXcel TherapeuticsPhase 3
30
BXCL501 + BXCL501 + Placebo filmBioXcel TherapeuticsPhase 2
17
BXCL501 + Placebo filmBioXcel TherapeuticsPhase 2
17
Sublingual film containing Dexmedetomidine + Sublingual Placebo FilmBioXcel TherapeuticsPhase 1/2
22